Get started
Author

Rosemary Senguttuvan

Observed name: Rosemary N Senguttuvan
OpenAlex ID: A5092083307
Safety and Efficacy of Cisplatin and Doxorubicin Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Patients with Ovarian Cancer with Peritoneal Metastases: A Multicenter US Phase I Trial
2025 · Brad Nakamura, Rosemary Senguttuvan, et al. · Annals of Surgical Oncology · 8
PDF
Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) experience in patients with recurrent low grade serous ovarian carcinoma (LGSOC): sub-cohort report of phase 1 clinical trial
2024 · Brad Nakamura, Rosemary Senguttuvan, et al. · Frontiers in Oncology · 6
PDF
The effect of food deserts on gynecologic cancer survival
2024 · Nicole Lugo Santiago, Philip H.G. Ituarte, et al. · Gynecologic Oncology Reports · 4
Safety and efficacy of PIPAC in patients with ovarian cancer with peritoneal metastases: A first-in-US phase I study.
2023 · Rosemary Senguttuvan, Daphne B. Stewart, et al. · Journal of Clinical Oncology · 4
PDF
Combining the prognostic role of age with molecular advances in the understanding of endometrial cancer
2024 · Rosemary N Senguttuvan, Joshua G Cohen · The Lancet Oncology · 2
Re-staging endometrial cancer patients according to the 2023 FIGO guidelines demonstrates no difference in survival by stage: A large, retrospective cohort validated by the TCGA dataset
2024 · Rosemary Senguttuvan, Nicole Lugo Santiago, et al. · Gynecologic Oncology · 1
T cells are critical for pre-metastatic niche formation through the STAT3/IL-17 axis
2026 · Maciej Kujawski, Antons Martincuks, et al. · Journal for ImmunoTherapy of Cancer
ASO Visual Abstract: Safety and Efficacy of Cisplatin and Doxorubicin Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Ovarian Cancer Patients with Peritoneal Metastases—A Multicenter U.S. Phase I Trial
2025 · Brad Nakamura, Rosemary Senguttuvan, et al. · Annals of Surgical Oncology
Association of race and ethnicity with survival outcomes in endometrial cancer patients with high-grade histologic subtypes
2025 · Rosemary Senguttuvan, Brad Nakamura, et al. · Gynecologic Oncology
Receipt of adjuvant radiotherapy increases survival in 2009 FIGO stage I endometrial cancer patients upstaged according to the updated FIGO 2023 guidelines
2025 · Rosemary Senguttuvan, Brad Nakamura, et al. · Gynecologic Oncology
Racial disparities in survival outcomes for uterine carcinosarcoma
2025 · Rosemary Senguttuvan, Brad Nakamura, et al. · Gynecologic Oncology
Low-grade endometrial cancer histology at diagnosis does not improve survival in the TP53 molecular subtype regardless of stage: A large, retrospective cohort validated by the Cancer Genome Atlas dataset
2024 · Rosemary Senguttuvan, Nicole Lugo Santiago, et al. · Gynecologic Oncology
PR043/#416 Restaging uterine cancer patients with the 2023 FIGO guidelines: clinical characteristics and survival differences
2023 · Rosemary Senguttuvan, Nicole Lugo Santiago, et al. · International Journal of Gynecological Cancer
PDF
EP017/#738 Insights from ovarian cancer patients’ rapid autopsy shed light on mechanisms of CD4+ T cell-mediated pre-metastatic niche formation through the STAT3 axis
2023 · Antons Martincuks, Rosemary Senguttuvan, et al. · International Journal of Gynecological Cancer
PDF
Gynecological cancer survival and association with food deserts (037)
2023 · Nicole Lugo Santiago, Philip Ituarte, et al. · Gynecologic Oncology
PDF
Minimally invasive surgery for endometrial cancer: A decade-long, 265,000 patient experience from the national cancer database (1234)
2023 · Rosemary Senguttuvan, Nicole Lugo Santiago, et al. · Gynecologic Oncology
PDF
The effects of the Covid-19 pandemic on practice patterns and outcomes in patients diagnosed with gynecologic malignancies in the United States.
2023 · Adrian Kohut, Nicole Lugo Santiago, et al. · Journal of Clinical Oncology
Works count: 17
Citation count: 25
H-index: 4
I10-index:
Year
Topic
Type